<?xml version="1.0" encoding="UTF-8"?>
<p>The cell surface protein, 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614" xmlns:xlink="http://www.w3.org/1999/xlink">angiotensin converting emzyme‐2 (ACE2)</ext-link> appears to be the most important receptor for SARS‐CoV‐2 to enter cells. This enzyme generates angiotensin‐(1–7), an endogenous pro‐resolution mediator (Barroso et al., 
 <xref rid="bph15164-bib-0007" ref-type="ref">2017</xref>; Magalhaes et al., 
 <xref rid="bph15164-bib-0023" ref-type="ref">2018</xref>). We have shown that Ang‐(1–7) exerted pro‐resolving actions during lung inflammation (Magalhaes et al., 
 <xref rid="bph15164-bib-0023" ref-type="ref">2018</xref>) and was protective in kidney, heart, and lung diseases (see Simões E Silva, Silveira, Ferreira, &amp; Teixeira, 
 <xref rid="bph15164-bib-0036" ref-type="ref">2013</xref>). Indeed, reduced levels of 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=1614" xmlns:xlink="http://www.w3.org/1999/xlink">ACE2</ext-link> increased SARS‐CoV‐induced lung injury by re‐directing the renin‐angiotensin system away from the ACE2/Ang‐(1–7) regulatory and protective pathway towards the pro‐inflammatory 
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=2504" xmlns:xlink="http://www.w3.org/1999/xlink">angiotensin II</ext-link> ‐
 <ext-link ext-link-type="uri" xlink:href="https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=34" xmlns:xlink="http://www.w3.org/1999/xlink">AT
  <sub>1</sub>
 </ext-link> receptor pathway. The effects of this re‐direction were attenuated by blocking the AT
 <sub>1</sub> receptors (Kuba et al., 
 <xref rid="bph15164-bib-0019" ref-type="ref">2005</xref>). It remains to be tested whether this pathway is defective in the context of COVID‐19 and whether the activation of the protective axis by administering the Ang‐(1–7) peptide or inhibiting the pro‐inflammatory pathways by blocking AT
 <sub>1</sub> receptors will constitute a protective approach to control the effects of COVID‐19.
</p>
